NRG-CC014, The PREEMPT Trial, Successfully Completes Accrual

04/15/2026

As of March 20, 2026, the study officially closed to accrual after successfully reaching its target enrollment of 280 patients. Accrual was completed in just 11 months, significantly ahead of the originally anticipated 29-month timeline. This exceptional achievement reflects the strong collaboration and commitment across all participating sites.

Special Recognition to our Top Accruing Sites:
Ohio State University Comprehensive Cancer Center – 29 participants
University of Vermont Medical Center – 12 participants
Fred Hutchinson Cancer Center/University of Washington – 12 participants
UT Health San Antonio – 10 participants
Moffitt Cancer Center – 10 participants

A Message of Gratitude from NRG-CC014 Study PIs – Drs. Erin Gillespie and Jonathan Yang
On behalf of the study leadership, we want to extend our deepest thanks to all participating sites. This accomplishment would not have been possible without the dedication of investigators, research coordinators, and administrative teams who worked to support patient enrollment and study execution. Your commitment has been exceptional!

Important Reminder for Investigators and What Comes Next
Skeletal Related Event (SRE) is the primary study outcome. Please ensure all SREs (including fractures, spinal cord compression, surgery for stabilization, and/or radiation for pain) are reported at each follow-up visit. These should be captured for enrolled lesions, as well as non-enrolled lesions. If events occur between visits, it is possible to record them immediately. Collection of PROs is also requested at time of SRE.

This trial represents an important step forward in advancing clinical care and improving patient outcomes. Thank you again for your partnership and dedication to this important work!